CAS No.: 956590-23-1
UNBS5162 Catalog No. CSN18633
UNBS5162 is a naphthalimide and a hydrolysis product of UNBS3157 that decreases CXCL chemokine expression in experimental prostate cancers and the mean antiproliferative activity IC50 value is 17.9 μM for 9 cancer cell lines.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
动物研究 剂量 Dog: 5 mg/kg, 15 mg/kg[2] (i.v.) Mice: 20 mg/kg[1] (i.v.); 80 mg/kg[1] (p.o.)
给药途径 i.v., p.o.
动物药代数据 Animal Nude mice[1] Dose 20 mg/kg (i.v.)
80 mg/kg (p.o.)Administration i.v.
p.o.F 3.84% (p.o.) Vd 18.9 L/kg (i.v.) T1/2 3.8 h (i.v.) Tmax 0.3 h (p.o.) CL 3.47 L/h/kg (i.v.) Cmax 12009 ng/ml (i.v.)
510 ng/ml (p.o.)AUC0→∞ 5767 ng·h/ml (i.v.)
886 ng·h/ml (p.o.)- 参考文献
- [1] Mijatovic T, Mahieu T, et al. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008 Jun;10(6):573-86.
- [2] Mahadevan D, Northfelt DW, et al. Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2013 Oct;18(5):934-41.
- [3] Mijatovic T, Mahieu T, Bruyère C, De Nève N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, Decaestecker C, Van Quaquebeke E, Darro F, Kiss R. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008 Jun;10(6):573-86. doi: 10.1593/neo.08290. PMID: 18516294; PMCID: PMC2386542.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 956590-23-1 | 储存条件 |
|
|||||
| 分子式 | C17H18N4O3 | 运输 | 蓝冰 | |||||
| 分子量 | 326.35 | 别名 | ||||||
| 溶解度 |
|
动物实验配方 |
